Controversies in the management of ovarian cancerOzols, R. F.International Journal of Gynecological Cancer: May-June 1997 - Volume 7 - Issue - p 27-32 Current Concepts In The Management Of Ovarian Cancer: Proceedings Of A Satellite Symposium Of The 1St European Symposium Of Epithelial Ovarian Cancer June 14, 1996 Abstract Author Information A new standard chemotherapy for ovarian cancer has been accepted in the USA: paclitaxel (Taxol®) plus a platinum compound (cisplatin or carboplatin). There remain, however, many areas of controversy in treating this disease, including the role of cytoreductive surgery, the optimum combination regimen, the approach to managing patients who achieve a clinical remission, the importance of dose intensity in chemotherapy, the efficacy of intraperitoneal therapy, the benefit of whole-abdomen irradiation, and the status of immunotherapy and hormones. Fox Chase Cancer Center, Philadelphia, PA, USA Address for correspondence: Dr R. F. Ozols, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. Taxol® is a trademark of Bristol-Myers Squibb Company. © 1997 Blackwell Science Ltd.